港股创新药板块持续走弱，百济神州跌超8%，药明生物跌超7%，泰格医药、康龙化成、诺诚健华跟 跌。 ...

摘要 ■ 投资逻辑 基于大模型对券商年度展望的全面解析 每年的年底到年初，各券商会密集发布关于总量、行业等年度报告。对投资者而言，难以整合大量研报信息从而提取共识点，此外分歧点也同样缺乏量化 对比。大模型工具的出现解决了这一难点，大模型可以帮助分析师快速完成研报数据预处理、观点精准抓取与分类；大模型通过确定共识点与分歧点的判 定规则，系统整合分散观点，量化呈现各券商对板块不同观点的支持率，清晰核心分歧维度。本次研究以大模型为核心分析工具，全面剖析2026年各大板 块年度展望，梳理宏观、策略、固收及七大细分行业的共识与分歧，为投资者提供高效精准的决策参考。 总量观点总结 对于总量观点，我们分别从宏观经济、年度策略、固定收益三个方面分别剖析了各券商分析师的年度展望。 在宏观经济方面，大多数券商认为随着"十五五"政策发力，2026年GDP目标为5%左右；CPI、PPI从低位逐步修复，国内通货膨胀的压力得到缓解；货币 政策维持适度宽松基调，流动性保持合理充裕；财政政策延续积极取向，赤字率维持合理高位；出口保持稳健，贸易顺差维持历史较高水平；国外环境虽 然出现波动，但整体风险可控。 作者：高智威、许坤圣 在年度策略方面 ...

Group 1 - The pharmaceutical sector is experiencing significant growth, with BD transaction volumes reaching new highs and domestic innovative drugs gaining international recognition, making it a focal point for investors [1][3] - However, there is a growing fatigue regarding the expectations for innovative drugs going abroad, leading to a shift from a "highlight moment" to a "volatile adjustment" in the market [2][3] - This transition is viewed as a necessary step towards a long-term market trend, with signs of recovery in the pharmaceutical sector as it approaches a new cycle starting in 2026 [3][11] Group 2 - The current investment rationale in the pharmaceutical sector is supported by three main forces: demand, supply, and policy, which are converging to fuel a new round of growth [5][36] - Demand for healthcare is increasing due to an aging population and rising health awareness, transforming medical consumption from optional to essential [6][37] - The supply side shows that China's innovative drugs are becoming globally competitive, with the number of innovative drug pipelines accounting for nearly 30% of the global total and BD overseas licensing transactions reaching $135.7 billion in 2025, a 161% increase year-on-year [7][38] Group 3 - Policy changes are shifting from cost control to empowerment, with new measures introduced to support the entire chain of innovative drug development, access, usage, and payment [10][41] - The Hong Kong stock market is becoming a primary platform for Chinese innovative drug companies due to its flexible listing regulations and foreign investment environment, which has attracted over 70 competitive innovative drug and CXO companies [12][43] - The establishment of the Hong Kong Medical Device Regulatory Center (CMPR) and other supportive mechanisms is expected to enhance the internationalization and business development capabilities of companies listed in Hong Kong [13][44] Group 4 - The Hang Seng Biotechnology Index has outperformed other indices with a 82.75% increase, highlighting its strong market position [16][46] - The index is composed of the top 30 biotechnology companies, focusing on high-growth sectors such as innovative drugs (79% weight) and CXO services (11% weight), ensuring coverage of the core segments of the pharmaceutical industry [17][49] - The index's unique feature includes being the only pharmaceutical-themed index in Hong Kong equipped with index futures, providing risk management tools and enhancing liquidity for investors [23][54] Group 5 - The Hang Seng Biotechnology Index is currently at a historically low valuation, with a PE ratio of 30.01, significantly lower than the NASDAQ Biotechnology Index and the CSI Biotechnology Index, indicating a valuation advantage [26][55] - The index's components are primarily leading innovative drug and CXO companies with solid R&D capabilities, suggesting potential for steady profit release as pipelines mature and orders are fulfilled [28][57] - The current market conditions may present a favorable opportunity for long-term investors to allocate resources into high-quality pharmaceutical assets through the Hang Seng Biotechnology ETF [29][58]

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The market turnover decreased to 82.799 billion HKD, with net inflows of 484 million HKD recorded in the Hong Kong Stock Connect [1] - The US stock market saw all three major indices rise, with the Dow Jones up 0.63%, S&P 500 up 0.81%, and Nasdaq up 1.26%, driven by Nvidia's strong earnings report [2] Sector Performance - In Hong Kong, local real estate, software, and 5G concept sectors faced significant declines, while gold stocks performed well [1] - The technology sector showed mixed results, with the Hang Seng Technology Index slightly down by 0.19% [1] - In the US, major tech stocks like Microsoft and Facebook saw gains, while the Nasdaq China Golden Dragon Index fell by 0.47% [2] Investment Opportunities - The report emphasizes the importance of "self-reliance in technology" and AI applications as key themes for future growth in the Hong Kong stock market, suggesting that leading companies in these sectors may see long-term development opportunities [3] - The recent policies from the Ministry of Industry and Information Technology regarding national computing power and communication infrastructure are expected to boost domestic computing and communication sectors [3] - Investors are advised to focus on sectors supported by policies aimed at expanding domestic consumption, such as sports apparel and non-essential services, as well as undervalued central state-owned enterprises with high dividends [3] Key Company Highlights - Haidilao (6862.HK) led the Hang Seng Index component stocks with a gain of 6.2%, while HSBC Holdings (0005.HK) and Longfor Group (0960.HK) rose by 5.5% and 4.6%, respectively [1] - The report notes that the recent adjustments in Shanghai's real estate policies are expected to release pent-up demand, benefiting core area property companies and their supply chains, such as Longfor Group and China Resources Land [10] - The Hong Kong government announced plans to issue licenses for stablecoin issuers and establish a committee focused on AI and industry development, which could benefit sectors related to digital assets and fintech [11]

Group 1: Market Performance - The A-share biopharmaceutical ETF Huatai Fuhua (159839) rose by 1.1%, with a total trading volume exceeding 22 million yuan, marking the fourth consecutive day of inflows totaling over 20 million yuan [2] - The Hong Kong biopharmaceutical ETF Huatai Fuhua (513280) fluctuated and closed flat, with a trading volume exceeding 42 million yuan, and a net inflow of over 17 million yuan in the last 60 days [3] - The majority of the popular component stocks in the biopharmaceutical ETF Huatai Fuhua (159839) showed positive performance, with Changchun High-tech hitting the daily limit and its subsidiary GenSci141 ointment receiving clinical trial approval [5] Group 2: Company Performance - WuXi AppTec (药明康德) reported a significant performance increase, with a projected net profit growth of 41.3% in 2025, driven by the TIDES business, which saw revenue growth exceeding 90% [8] - WuXi Biologics (药明生物) achieved a record total of 945 projects, with a 30% growth in dual monoclonal antibodies and ADC projects, indicating strong future revenue potential [8] - The domestic clinical CRO market is expected to return to a growth trajectory in 2025, benefiting companies like Tigermed (泰格医药) from improved order prices and increased clinical pipeline numbers [8] Group 3: Industry Trends - The global CXO industry is expected to continue its strong recovery, with significant investment and transaction demand in the biotech and pharmaceutical sectors anticipated to rebound in 2025 [7] - The Chinese innovative drug market is showing robust activity, with a 19% year-on-year increase in IND numbers and a substantial rise in BD transaction amounts, indicating a vibrant domestic market [7] - The Chinese innovative drug sector is transitioning from pipeline expectations to revenue realization, with over 70% of companies projected to achieve positive revenue growth in 2025 [11]

消息面上，北海康成此前宣布，向药明生物旗下子公司配售8,403.36万股股份，占扩大后股本约 14.12%。配股事项所得款项净额约1.99亿港元，约12%将用于商业化产品的营运资金及注册维护；28% 用于现有产品线的研发开支；60%用于结算集团的贸易应付款项。配售完成后，药明生物于北海康成的 持股比例将升至约16.27%。 智通财经获悉，北海康成-B(01228)午后涨超6%，截至发稿，涨5.68%，报2.79港元，成交额172.27万港 元。 本文源自：智通财经网 ...

北海康成-B(01228)午后涨超6%，截至发稿，涨5.68%，报2.79港元，成交额172.27万港元。 消息面上，北海康成此前宣布，向药明生物旗下子公司配售8,403.36万股股份，占扩大后股本约 14.12%。配股事项所得款项净额约1.99亿港元，约12%将用于商业化产品的营运资金及注册维护；28% 用于现有产品线的研发开支；60%用于结算集团的贸易应付款项。配售完成后，药明生物于北海康成的 持股比例将升至约16.27%。 ...

消息面上，北海康成此前宣布，向药明生物旗下子公司配售8,403.36万股股份，占扩大后股本约 14.12%。配股事项所得款项净额约1.99亿港元，约12%将用于商业化产品的营运资金及注册维护；28% 用于现有产品线的研发开支；60%用于结算集团的贸易应付款项。配售完成后，药明生物于北海康成的 持股比例将升至约16.27%。 智通财经APP获悉，北海康成-B(01228)午后涨超6%，截至发稿，涨5.68%，报2.79港元，成交额172.27 万港元。 ...

张玮航 国联民生证券医药分析师: 各位投资者，大家这个上午好。那个开年第一天，大家开工大吉。那首先感谢大家来参加 我们国联民生。医药团队的这个电话会，今天是那个北海康成的这个近期情况的更新的电 话会议。我是那个，就是国内民生的研究员张金阳，在线跟我一起主持的还有我们团队的 胡若冰胡博，还有那个郭王洋。那节前，我们团队也组织了在康城的这个电话会，当时是 从这个罕见病行业的角度，这个当时这个邀请了薛总和百洋的这个副总来跟大家做了一个 沟通。那今天，这个电话会的主要的这个内容，是盖康城其实在春节期间，我们看到了一 个公告，这个配收了这个 8400 万股的这个股份给这个药明生物子公司，募集了 2 亿港元。 这个公告里面这个说这 2 亿港元的 12%用于商业化这个产品的运营。28%用于这个管线 的这个研发开支，60%用于这个结算集团的贸易应付款，那也，这个另外也补充公告了这 个售出现有股票的这个单位，其中一名服务供应商向本集团提供发展这个策略咨询，而另 一名的这个服务供应商就是，就要药物监管审批事宜，向本集团提供这个监管咨询，这些 相关的公告内容，我相信大家也看到了。那我们今天，针对这件事，也是很荣幸的再次请 到了这个 ...

Group 1 - The Hong Kong stock market experienced a decline in major tech stocks, with Tencent Holdings and Meituan dropping over 3%, while Alibaba, Baidu Group, and Xiaomi Group fell by 2% [1] - Southbound capital saw a reversal from net outflow to net inflow, with a rapid net inflow of HKD 3.1 billion in the last half hour before the market closed [1] - Significant buying activity was observed in the Hang Seng Technology Index ETF (513180.SH) and the Hang Seng Internet ETF (513330.SH), with over HKD 1 billion in large orders during a sharp intraday drop, indicating potential bullish sentiment towards Hong Kong tech assets [1] Group 2 - Investment opportunities are identified in Hong Kong tech-related ETFs, including the Hang Seng Technology Index ETF (513180.SH), Hang Seng Internet ETF (513330.SH), and the Hong Kong Stock Connect Technology ETF (159101.SZ) [2] - The Hang Seng Internet ETF (513330.SH) focuses on major Hong Kong internet giants such as Alibaba, Baidu Group, Tencent Holdings, and NetEase, while the Hong Kong Stock Connect Technology ETF (159101.SZ) also includes leading innovative pharmaceutical companies [2] - These ETFs are listed on the Shanghai and Shenzhen stock exchanges, allowing A-share investors to trade flexibly with low entry barriers and without the need for cross-border accounts or currency exchange [2]